A new tool from the state of Ohio aims to help officials proactively address heightened drug overdose risk in local ...

The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi that the agency recommended for approval in November for some patients with early ...

Paul Howe, chief commercial officer at Protega Pharma, discusses how regulatory agencies are updating their policies based on the presence of abuse-deterrent medications. Pharmaceutical Executive: How ...

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...

Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid ...

Cancer drug response prediction is a critical area of research aimed at personalizing cancer treatment. With the increasing complexity of cancer and the variability in how patients respond to ...

Recent cases have highlighted differing legal responses to drug abuse. While some individuals struggling with substance use are sent to rehabilitation, others face prosecution and possible prison ...

The research over the next two years will be used to help agencies across the country best intervene in the ongoing substance ...

The genetic polymorphisms that may affect individual responses to cardiovascular agents are reviewed, and the application of pharmacogenetics to cardiovascular disease management is discussed.

Two overarching goals tied to a futuristic vision of personalized medicine are to maximize individually derived benefits from available therapeutic drugs or biological agents and identify a ...